Motoya, S., Maemoto, A., Fujiya, M., Ashida, T., Goto, M., Matsumoto, T., . . . Hibi, T. (2022). AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology & Hepatology, 7(7), 648-657. https://doi.org/10.1016/S2468-1253(22)00022-X

Motoya, Satoshi, et al. "AJM300 (carotegrast Methyl), an Oral Antagonist of α4-integrin, as Induction Therapy for Patients with Moderately Active Ulcerative Colitis: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study." The Lancet Gastroenterology & Hepatology 7, no. 7 (2022): 648-657. https://doi.org/10.1016/S2468-1253(22)00022-X.

Motoya, Satoshi, et al. "AJM300 (carotegrast Methyl), an Oral Antagonist of α4-integrin, as Induction Therapy for Patients with Moderately Active Ulcerative Colitis: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study." The Lancet Gastroenterology & Hepatology, vol. 7, no. 7, 2022, pp. 648-657, https://doi.org/10.1016/S2468-1253(22)00022-X.